Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

By K. Swedberg, M. Komajda, M. Böhm, J. Borer, Ian Ford, Ariane Dubost-Brama, G. Lerebours, L. Tavazzi. The Lancet, 2010

2,142 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “, and an EF ≤35%.(112) Patients were also required to have had a HF hospitalization in the previous 12 months.”
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2016, neutral): “Downloaded from https://academic.oup.com/eurheartj/article-abstract/37/27/2129/1748921 by Rijksuniversiteit Groningen user on 27 November 2017 MRA.”
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) (2012, positive): “and reduced left ventricular function (either coronary artery disease or heart failure), trials of pure heart rate reduction have shown benefit.(64,65) There is not enough evidence, at present, to recommend a target heart rate.”
2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. (2019, background): “The 2016 recommendations of the AHA/ACC(7) and ESC guidelines(9) include new drugs: the angiotensin receptor-neprilysin inhibitor (valsartan/sacubitril(193)) and the sinoatrial modulator, ivabradine.(193,194) The therapy for congestive symptoms includes loop diuretics and volume control, with recomm”